University of Chicago: Colorectal Neoplasms trials
The registry lists 12 Colorectal Neoplasms studies with University of Chicago as lead sponsor. 3 are open to participants now and 0 have results posted.
Phase 1 5Phase 2 6No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Collagenase Biobank StudyNot yet recruitingNCT07211230
- FITting Non-invasive Tests in Lynch Syndrome SurveillanceRecruitingNCT06898996Not applicable
- Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following SurgeryRecruitingNCT06349590Phase 1/2
- A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal CancerSuspendedNCT05200442Phase 1/2
- Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal MetastasisActive, not recruitingNCT04157322
- Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal CancerWithdrawnNCT02573220Phase 1
- A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer PatientsCompletedNCT01183494Phase 1
- Do Patients With Colorectal Cancer Understand That Their Family is at Risk?TerminatedNCT00145860
- Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal CancerCompletedNCT00026299Phase 1/2
- BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal CancerCompletedNCT00022477Phase 2
- Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal CancerCompletedNCT00003950Phase 2
- Irofulven in Treating Patients With Metastatic or Recurrent Colorectal CancerWithdrawnNCT00003786Phase 2